Erik van Munster

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

Karen Ribbons, Patrick McElduff, Cavit Boz et al. · PLoS ONE · 2015 · 188 citations · Full text

Medicine, Biostatistics, Neurology +16

Conformational changes in CLIP-170 regulate its binding to microtubules and dynactin localization

Gideon Lansbergen, Yulia Komarova, Mauro Modesti et al. · The Journal of Cell Biology · 2004 · 180 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +12

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis

Tomáš Kalinčík, Timothy Spelman, María Trojano et al. · PLoS ONE · 2013 · 130 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +17

Risk of relapse phenotype recurrence in multiple sclerosis

Tomáš Kalinčík, Katherine Buzzard, Vilija Jokubaitis et al. · Multiple Sclerosis Journal · 2014 · 108 citations · Full text

Life Sciences, Neurology, Neuroscience +11